Slide 1: First Quarter 2022 Financial Results & Business Update
First Quarter 2022 Financial Results & Business Update April 27, 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkerm
Slide 3: Agenda
Agenda Introduction Sandy Coombs, SVP, Investor Relations & Corporate Affairs Q1 2022 Financial Results Iain Brown, Chief Financial Officer Q1 2022 Commercial Review Todd Nichols, Chief Commercial Officer Business and R&D Pipeline Update Richard Pops, Chief Executive Officer
Slide 4: Q1 2022 Financial Results Summary
In millions In millions In millions Q1 2022 Financial Results Summary *GAAP net loss for Q1’22 included a reduction of $19.1M in the fair value of contingent consideration related to increased risk of non-payment of certain milestone payments by Baudax Bio, Inc. in light of its disclosures regarding
Slide 5: First Quarter 2022 Revenue Summary
First Quarter 2022 Revenue Summary Amounts in the table above may not sum due to rounding. *Inclusive of ARISTADA INITIO® **In Q1'22, royalty revenues from INVEGA SUSTENNA®/XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA® (the “long-acting INVEGA products”) were $37.1M, compared to $61.6M in Q
Slide 6: Alkermes: 2022 Financial Expectations
Alkermes: 2022 Financial Expectations* *These expectations were initially provided by the Company on Feb. 16, 2022, are reiterated by the Company on April 27, 2022 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations These ex
Slide 7: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations Q1’22 year-over-year net sales increased 14% to $84.9M, driven by unit growth of 7% Gross-to-net deductions: 49.4% in Q1’22, compared to 51.5% in Q1’21 Inventory levels decreased sequentially by ~$4M, in line with typical seasonal patterns FY’22 net sales expec
Slide 8: ARISTADA Performance and Expectations
ARISTADA® Performance and Expectations Q1’22 year-over-year net sales increased 31% to $72.5M, driven by unit growth of 27% Gross-to-net deductions: 53.4% in Q1’22, compared to 53.3% in Q1’21 Inventory levels remained flat on a sequential basis, as expected FY’22 net sales expected to range from $29
Slide 9: ARISTADA Prescription Growth Trends
ARISTADA® Prescription Growth Trends Q1’22 year-over-year growth of 13% on TRx months of therapy (MOT) basis Outpaced overall atypical long-acting injectable (LAI) market Q1’22 year-over-year growth of 7% Market share: TRx MOT: 9.8% of atypical LAI market prescriptions in Q1’22 ARISTADA Quarterly TR
Slide 10: LYBALVI Performance and Expectations
LYBALVI® Performance and Expectations LYBALVI Quarterly Net Sales ($M) † These expectations were initially provided by the Company on Feb. 16, 2022, are reiterated by the Company on April 27, 2022 and are effective only as of such date. The Company expressly disclaims any obligation to update or rea
Slide 11: LYBALVI Prescription Growth Trends
LYBALVI® Prescription Growth Trends *Source: IQVIA NPA Weekly ** ** ** ** Holiday week Q1’22 total TRx: ~10,400 Since launch, ~2,650 prescribers had written a prescription for LYBALVI, supported by a competitive share of voice in the market and growing awareness levels among prescribers
Slide 12: Looking Ahead: 2022 Strategic Priorities
Looking Ahead: 2022 Strategic Priorities Execute successful LYBALVI® launch and continue to establish payer access profile Drive growth of VIVITROL® in alcohol dependence indication and increase ARISTADA® share of aLAI market Commercial Portfolio Nemvaleukin Early-stage Pipeline Financial Advance en
Slide 13: Appendix
Appendix Confidential, Internal Use Only
Slide 14: Appendix: Financial Results GAAP to Non-GAAP Adjustments
Appendix: Financial Results GAAP to Non-GAAP Adjustments
Slide 15: Appendix: 2022 Guidance GAAP to Non-GAAP Adjustments
Appendix: 2022 Guidance GAAP to Non-GAAP Adjustments Projected GAAP and non-GAAP measures reflect mid-points within ranges of estimated guidance.
Slide 16: www.alkermes.com
www.alkermes.com